Record Sales Surge
Galderma's net sales hit record $3.134 billion in H1 2026, growing 24.6% and raising guidance
Anonymous
Galderma crossed a major milestone in the first half of 2026, posting record net sales of $3.134 billion — the first time the dermatology company has surpassed $3 billion in a single six-month period. Year-on-year growth hit 24.6% at constant currency, driven largely by volume gains and a favorable product mix, according to Edmonton Sun.
On the back of the strong results, Galderma raised its full-year net sales guidance. The company said it continues to outperform the broader market across each of its product categories, from injectable aesthetics to dermatological skincare, according to The Sudbury Star.
Injectable Aesthetics and Biostimulators Power the Surge
Injectable Aesthetics was the company's largest single segment, generating $1.437 billion in net sales for the first half. That segment grew 12.1% year-on-year at constant currency, according to Seaforth Huron Expositor. Restylane, a key filler brand, also received new indications approved in the U.S., expanding its commercial reach.
Injectables and Biostimulators delivered even faster growth. Net sales climbed 10.5% year-on-year at constant currency, with overall year-on-year growth reaching 13.4%, The Whig reported. Sculptra, Galderma's biostimulator, is being scaled up in China, adding a major new growth market to the brand's footprint.
Skincare Brands Gain Ground in U.S. and Global Markets
Galderma's dermatological skincare division is also outpacing rivals. The company said it gained market share in both the U.S. and international markets through its Cetaphil and Alastin brands, according to Ontario Farmer. Cetaphil is one of the world's most recognized sensitive-skin brands, while Alastin targets post-procedure skincare.
The dual-brand strategy is working. Geographic expansion is ongoing, and the skincare segment is contributing meaningfully to the company's overall volume growth, Woodstock Sentinel Review reported. Galderma did not break out specific skincare revenue figures in this release.
FDA Sends Complete Response Letter on Manufacturing Issues
Not all news was positive. The U.S. Food and Drug Administration issued Galderma a Complete Response Letter, or CRL. A CRL means the FDA is not yet ready to approve a product. In this case, the agency flagged remaining concerns about a manufacturing site and the need to optimize an analytical method, according to Northern News.
Galderma said it is committed to resolving the FDA's observations. The company did not give a timeline for resubmission. Regulatory setbacks of this kind are common in the industry but can delay product launches by months or longer, Fort McMurray Today reported.
Raised Guidance Signals Confidence in Second Half Momentum
Despite the FDA hurdle, Galderma raised its net sales guidance for the full year 2026. That move signals management's confidence that the strong first-half pace can continue. The company's growth is being fueled by volume, not just price increases — a sign of genuine demand, according to Cold Lake Sun.
Galderma operates in the fast-growing medical aesthetics and dermatology space. Both markets have shown resilience even in uncertain economic environments. With Sculptra expanding in China and new Restylane indications in the U.S., the pipeline of growth drivers remains active heading into the second half of 2026, The Observer reported.
Sentiment
NeutralNEGATIVENEUTRALPOSITIVE
Publishers
13
Articles
13
Reach
13
A
AnonymousAuthor